Analysis – Page 22 – Goldea Capital

Century Therapeutics Reports First Quarter Financial Results and Business Updates

Written by Customer Service on May 13, 2026. Posted in Earnings Releases And Operating Results.

CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027 Upcoming oral presentation at the American Diabetes Association (ADA) annual Scientific Sessions highlighting CNTY‑813 preclinical data on June 8, 2026 On track to advance CNTY‑308, Century’s CD19‑targeted CAR‑iT cell therapy, into the clinic this year Cash runway into 1Q 2029 with cash, cash equivalents, and marketable securities of $217.0 million as of March 31, 2026PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results...

Photronics to Report Fiscal Second Quarter 2026 Results on May 28, 2026

Written by Customer Service on May 13, 2026. Posted in Earnings Releases And Operating Results.

BROOKFIELD, Conn., May 13, 2026 (GLOBE NEWSWIRE) — Photronics, Inc. (Nasdaq: PLAB), a worldwide leader in photomask technologies and solutions, is scheduled to announce financial results for the second quarter of fiscal 2026 on Thursday, May 28, 2026, before the market opens. Photronics will host a public conference call the same day at 8:30 a.m. Eastern time. During the call, company management will respond to questions concerning, but not limited to, the company’s financial performance, business conditions, and industry outlook. Some responses may contain information not previously disclosed. The call will be broadcast live and on-demand on the Events and Presentations link on the Photronics website. Analysts and investors who wish to participate in the Q&A portion of the call should click here: Conference Registration....

LiqTech International Announces First Quarter 2026 Financial Results

Written by Customer Service on May 13, 2026. Posted in Earnings Releases And Operating Results.

BALLERUP, Denmark, May 13, 2026 (GLOBE NEWSWIRE) — LiqTech International, Inc. (Nasdaq: LIQT) (“LiqTech”), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the first quarter of 2026. Recent Financial HighlightsQ1 2026 revenue of $4.1 million compared to $4.6 million in Q1 2025. Q1 2026 net loss of $(2.7) million compared to $(2.4) million in Q1 2025. Q1 2026 Adjusted EBITDA of $(1.5) million compared to $(1.4) million in Q1 2025. Ending cash balance of $2.7 million on March 31, 2026.OutlookThe Company is reiterating its expectation for FY 2026 revenue between $23 million and $27 million, which would represent an increase of 39% to 64% over FY 2025.Recent Operational HighlightsElevated Commercial Pool activity with...

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Written by Customer Service on May 13, 2026. Posted in Earnings Releases And Operating Results.

The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion leader (KOL) perspectives on May 19, 2026 at 4:30 pm ET Interim safety and durability data from STARBORN-1 trial of TARA-002 in LMs to be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026 in May Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial and initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026 Presenting updated 12-month data from Phase 2 ADVANCED-2 trial of TARA-002 in patients with high-grade, BCG-Naïve non-muscle invasive bladder cancer (NMIBC) at the American Urological Association (AUA) Annual...

Swarmer Reports First Quarter Financial Results

Written by Customer Service on May 13, 2026. Posted in Earnings Releases And Operating Results.

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) — Swarmer, Inc (“Swarmer” or the “Company”) (Nasdaq: SWMR), a drone autonomy software company which has supported more than 100,000 real-world combat missions in Ukraine since April 2024, today announced financial results for the quarter ended March 31, 2026 (“Q1 2026”), and discussed recent business developments. Management CommentarySwarmer President & U.S. CEO Alex Fink stated: “The first quarter of 2026 represented an important step forward for Swarmer as we completed our initial public offering, strengthened our leadership team and continued to expand our presence within the autonomous systems ecosystem. These milestones support our ability to pursue a rapidly expanding market, as demand for autonomous and collaborative unmanned systems continues to accelerate amid rising deployment...

Astrotech Reports Third Quarter of Fiscal Year 2026 Financial Results

Written by Customer Service on May 13, 2026. Posted in Earnings Releases And Operating Results.

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the third quarter of fiscal year 2026, which ended March 31, 2026. Financial Highlights & Recent DevelopmentsResearch and development expense was $554 thousand, a decline of 28% from the third quarter of fiscal year 2026 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect TRACER 1000 product lines. Through March 31, 2026, the Company has deployed the TRACER 1000 trace detection system in approximately 37 locations in 16 countries across the United States, Europe and Asia.“During the third quarter of fiscal year 2026, we remained focused on disciplined execution, achieving targeted cost-efficiency initiatives while...

Totaligent Enters APAC Medical Tourism Market at Historic Inflection Point, as Global Healthcare Travel Surges Toward $274 Billion

Written by Customer Service on May 13, 2026. Posted in Mergers And Acquisitions.

Aetherium Medical Platform Positions Totaligent at the Center of Asia-Pacific’s Booming Demand for Advanced Biologics and Medical-Grade Travel BOCA RATON, Fla., May 13, 2026 (GLOBE NEWSWIRE) — Totaligent, Inc. (OTCID: TGNT) (“Totaligent” or “the Company”), an emerging leader in specialized infrastructure platform for the blossoming biologics space and intelligent business marketing data, today announced the strategic commercial positioning of its soon to be acquired Aetherium Medical platform as a direct response to one of the most significant structural shifts in global healthcare: the explosive, government-backed surge in medical tourism across Asia-Pacific, a global market now projected to reach $273.7 billion by 2032. The move follows Totaligent’s April 15, 2026 Definitive Agreement for the acqui-hire of the Aetherium...

Swarmer Awarded $2.86M Contract to Outfit SkyKnight Drones With Swarming Software

Written by Customer Service on May 13, 2026. Posted in Public Companies.

Software license allocations to Kyiv-based Meta Bureau LLC could yield up to $13.2 million for Swarmer if all contract options are exercised TALLINN, Estonia, May 13, 2026 (GLOBE NEWSWIRE) — Swarmer, Inc. (“Swarmer” or the “Company”) (NASDAQ: SWMR), a drone autonomy software company which has supported more than 100,000 real-world combat missions in Ukraine since April 2024, today announced that Meta Bureau LLC awarded its subsidiary, Swarmer Estonia OÜ, a contract with an initial value of $2.86 million for more than 16,000 software licenses to be used aboard its SkyKnight quadcopter bombers and other unmanned aerial vehicles (UAVs). The contract also allows Meta Bureau to elect to upgrade certain licenses for an additional $10.4 million. “Just like Meta Bureau, Swarmer’s technology is battle-proven and able to work together seamlessly...

InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

Written by Customer Service on May 13, 2026. Posted in Public Companies.

– Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ICP-054 (ZB021) in healthy volunteers – Phase 1 SAD and MAD data expected by year-end 2026 BEIJING, May 13, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in the Phase 1 trial of ICP-054 (ZB021), a novel potentially best-in-class oral IL-17AA/AF inhibitor. The Phase 1 trial is supported by robust preclinical data demonstrating a desirable pharmacology and toxicology profile. In addition to potent inhibition of IL-17AA/AF signaling, and anti-inflammatory activity demonstrated in preclinical animal models, excellent oral bioavailability was observed across...

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Written by Customer Service on May 13, 2026. Posted in Public Companies.

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:2026 RBC Capital Markets Global Healthcare Conference, fireside chat on Wednesday, May 20, 2026 at 11:00 a.m. ET in New York, NY 2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 9:55 a.m. ET in New York, NY Goldman Sachs 47th Annual Global Healthcare Conference 2026, hosting meetings on Tuesday, June 9, 2026 in Miami, FLA live webcast of each fireside chat will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals